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Available online 25 December 2015AbstractThe burden of norovirus (NoV) gastroenteritis is substantial in young children. Maternal antibodies are thought to protect a child from NoV
infection in early infancy but subsequent development of NoV-specific protective immunity in children is still largely unexplored.
We have determined NoV-specific antibody seroconversion to GII.4 virus-like particles as an indicator of NoV infection in two children
prospectively followed from birth to eight years of age. Blocking activity and affinity maturation of maternal and serum IgG antibodies were
evaluated.
Our results show that multiple infections occur in children up to eight years of age. The titer, blocking activity and avidity of maternal
antibodies determined susceptibility of an infant to NoV infection. NoV GII.4-specific antibodies with high blocking potential and avidity were
developed at two to three years of age and were retained throughout the follow-up. Subsequent NoV infections may have contributed to the
duration of protective NoV-specific immune responses that lasted for several years.
This study adds to current understanding of the duration of passive protection by maternal antibodies and the duration and quality of acquired
immunity following primary and subsequent NoV infections in infants and young children, who are the main target group for NoV vaccine
development.
© 2016 The Authors. Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Infants and children under five years of age are most sus-
ceptible to norovirus (NoV) acute gastroenteritis (AGE)
[1e3], and are therefore one of the potential target groups for
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).shedding compared to adults [4] and may be considered as a
pool for transmission of NoV to other vulnerable populations,
e.g. senior citizens. NoV infects all age groups and in adults
the NoV seropositivity is near 100% as a result of lifetime
NoV exposure history [5].
Most NoVs infecting humans belong to genogroups GI and
GII, which are genetically so distant that no intergenogroup
cross-protective immune responses are generated [6]. How-
ever, after natural infection [7e11] and also vaccination [12]
variable degree of intragenogroup cross-reactivity has been
observed. NoV GII.4 genotype is responsible fornstitut Pasteur. This is an open access article under the CC BY-NC-ND license
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[13e15]. New epidemic antigenically distinct GII.4 variants
emerge every two to three years [16e18] but considerable
antibody cross-reactivity between GII.4 variants has been
observed even in young children [19].
Correlates of protective immunity to NoV are not well
established. A common finding has been that protection is not
long lasting [5]. Early homologous challenge studies by Par-
rino et al. [20] and Johnson et al. [21] have shown that
duration of protective immunity varies from two months to
two years. There are a limited number of studies on NoV-
specific immune responses in children. In contrast to those
of adults, IgG responses to NoV during the first year of life are
relatively weak and short-lived and the antibodies are of a low
avidity [22,23]. Saito et al. [24] found that most infections in
less than six-month-old infants are asymptomatic, probably
due to maternally acquired antibodies and, possibly, breast-
feeding. Altogether, the build-up of protective immunity after
primary and secondary NoV infections is not well
characterized.
NoV virus-like particles (VLPs) are commonly used for
studying immune responses against NoV. The expression of
the NoV capsid VP1 protein results in formation of VLPs that
are morphologically and antigenically similar to native virions
[25], thereby being also promising vaccine candidates [26,27].
Blocking assay has been used as a surrogate measure for NoV
neutralization, determining the ability of serum antibodies to
block binding of NoV VLP to its putative histo-blood group
antigen (HBGA) receptors/attachment factors [12,28,29]. We
have previously used NoV GII.4 VLPs to determine NoV
seroprevalence in Finnish children [10]. Also, more recently
an endpoint titer >51,200 and/or 90% blocking titer (BT90)
>100 was suggested as an indicator of protection from NoV
infection in these children [10]. The recent challenge studies
in adults have further affirmed correlation between the
blocking antibodies and protection [12,30]. Antibody avidity
is low in primary and recent NoV infections and increases with
time [23], but the relevance of the Ab avidity in NoV pro-
tective immunity is not currently known.
In this study we determined seroconversion to NoV GII.4
VLPs as an indicator of NoV infection in two children pro-
spectively followed from birth up to the age of eight years and
examined the duration, blocking ability, and avidity of the
antibodies.
2. Materials and methods2.1. Study samplesTwo healthy children (Subject 1 and 2) taking part in the
Type I Diabetes Prediction and Prevention (DIPP) study [31]
were prospectively followed for NoV GII.4-specific anti-
bodies from birth to eight years of age. The DIPP study
protocol was approved by the ethics committee of the Pir-
kanmaa Hospital District (Permit number: 97193M) and a
written informed consent was obtained from the parents.
Health records were collected during the follow-up visitsand symptoms related to acute gastroenteritis episodes were
recorded. Subject 1 had been breastfed exclusively for first
five months and partially until the age of 25 months.
Breastfeeding of the Subject 2 was exclusive for first two
months, partial for one month. All procedures performed
were conducted according to the principles expressed in the
Declaration of Helsinki. Cord blood samples were taken at
birth in year 2000 and thereafter blood samples were taken
in sodium citrate tubes at the age of 3, 6, 12, 17 and 24
months and thereafter once per year up to eight years of age.
Plasma fraction was stored at 70 C until analyzed. Non-
diarrheal stool samples were collected monthly at the age
of 3e9 months and every two months until the age of 1 year,
9 months. Viral RNA was extracted from the stool suspen-
sions and stored at 70 C until reverse transcription-
polymerase chain reaction (RT-PCR) and open reading
frame 1 polymerase (region A) sequencing were used for
NoV genotyping according to previously described methods
[32].2.2. Norovirus VLP productionGII.4-1999 capsid VP1 sequence originated from a patient
sample collected in 1999 (GenBank reference strain accession
no. AF080551) [23,33]. NoV GII.4-1999 VLPs used as anti-
gens in analytical methods were produced by a baculovirus
expression system (Invitrogen) in Spodoptera frugiperda (Sf9)
insect cell cultures. VLPs were purified twice with discon-
tinuous sucrose gradient ultracentrifugation as previously
described [33]. The total protein concentration was quantified
with Pierce® BCA Protein Assay (Thermo Scientific, Rock-
ford). Protein purity, integrity, and morphology were deter-
mined by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), western blotting and trans-
mission electron microscopy (EM) as described earlier
[26,33].2.3. Serum IgG ELISANoV GII.4-1999-specific IgG antibody levels were
analyzed by ELISA as earlier described [10]. Serum speci-
mens were diluted two-fold starting at 1:100 and plated on
GII.4-1999 VLP coated (0.5 mg/ml in phosphate-buffered sa-
line, PBS) 96-well half-area microtiter plates (Corning Inc.,
Corning, NY) blocked with 5% skimmed milk in PBS. Serum
dilutions were incubated on plates for 1 h at 37 C. Bound
GII.4-1999-specific antibodies were detected with goat anti-
human IgG-HRP (Invitrogen, CA, USA) followed by o-phe-
nylenediamine (OPD) substrate (SigmaeAldrich, MO, USA)
and H2O2. Optical density (OD) was measured at l 490 nm
using the Victor2 1420 Multilabel Counter (Wallac, Perkin
Elmer) plate reader. Background signal from the blank wells
(wells without serum) was subtracted from all of the OD
readings on the plate. Each plate contained NoV negative and
positive control serum sample as an assay control. The cut-off
value was determined as the mean OD reading of the negative
control serum wells at a dilution 1:200 þ 3  standard error
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reciprocal of the final serum dilution giving an OD above the
cut-off value. Seroconversion was defined as at least four-fold
increase in the titer of successive sera.2.4. Avidity assayAvidity of serum IgG antibodies was determined in
ELISA by urea elution steps according to a previously pub-
lished method [23,34]. Sera were tested at 1:100 dilution on
GII.4-1999 VLP (1.0 mg/ml) coated and blocked microtiter
plates. After incubation for 1 h at 37 C, wells were exposed
twice for 5 min to 8 M urea in PBS-Tween solution or to
phosphate buffer. After washing, the wells were incubated
with peroxidase-labeled anti-human IgG and bound anti-
bodies were detected as described above. Avidity index (%)
was calculated using the equation: [OD with urea/OD
without urea]  100%. An avidity index >50% was consid-
ered as high avidity [7,23].2.5. Blocking of HBGA bindingThe ability of antibodies to block GII.4-1999 VLP binding
to synthetic HBGA was tested using H type 1 HBGA car-
bohydrates that have been shown to be biologically relevant
for NoV attachment in infection [28] as well as to bind to
GII.4 NoV VLPs [35]. The blocking assay was carried out as
previously described [35]. Briefly, the pre-coated and pre-
blocked NeutrAvidin plates (Pierce, Rockford, IL) were
coated with H type 1 (Glycotech, Gaithersburg, MD) HBGAs
for 1 h at room temperature. Serially two-fold diluted serum
samples starting at 1:50 dilution were first preincubated with
NoV GII.4-1999 VLPs (0.4 mg/ml) for 1 h at 37 C, before
incubating the samples on HBGA-coated NeutrAvidin plates
for 2 h at þ4 C. Bound VLPs were detected by GII.4-1999-
specific mouse antisera and anti-mouse IgG-HRP (Sigma-
eAldrich, Saint Louis, MO), followed by OPD substrate and
H2O2. Mean OD reading of the blank wells was subtracted
from the OD values of the sample wells. A maximum binding
signal was the mean OD of the wells with VLP alone, lacking
serum. The blocking index was defined as follows: 100 e
[OD for wells with serum/OD for wells without
serum]  100. A blocking titer (BT) value of 50 or 90 was
determined as the reciprocal of the final serum dilution that
blocked at least 50% or 90% of VLPs binding to the HBGA.
For statistical analyses an arbitrary BT of 25 (half of the
starting reciprocal serum titer 50) was assigned to all sera
which lacked blocking.2.6. Statistical analysisThe Spearman rank correlation coefficient was used to
examine the differences between antibody titers, blocking ti-
ters BT90 and avidity index. All hypothesis testing was two-
tailed. Statistical analyses were performed using IBM SPSS
Statistics (SPSS, Chicago, IL) version 22.0. P < 0.05 was
considered statistically significant.3. Results
The integrity and morphology of NoV GII.4 VLPs used for
the analytical methods were verified by western blot (Fig. 1A)
and EM (Fig. 1B). EM images identified NoV VP1 capsid
proteins self-assembled into the VLPs of ~38 nm in size.
The Subject 1 had moderate levels (endpoint titer 3200) of
GII.4-1999-specific cord blood antibodies that waned in the
following three months (Fig. 2 and Table 1). Seroconversion to
NoV GII.4 VLPs was observed at the age of six months and
again at the three and five years of age, indicating at least three
NoV infections by this age. No NoVs were detected in the
stool samples of the Subject 1 collected during the first two
years of life. Only one episode of AGE between the age of
17e24 months had been recorded for Subject 1, which did not
coincidence with the stool or serum samples collected.
Despite the seroconversion, the primary NoV exposure
before the age of six months did not increase the blocking
(BT90 < 50) or avidity index (19%) of GII.4-1999-specific
antibodies (Table 1). Blocking antibodies with BT90 value of
100 and high avidity (95% avidity index) were observed after
the presumably second NoV infection at the age of three years.
The ability to block the binding of VLPs to HBGA ligand
declined within one year (BT90 < 50), but remained still above
the initial level until the age of seven years (BT50 50). Simi-
larly, the avidity index declined within one year to 67%, but
remained >50% for all the subsequent time points. A two-fold
increase in endpoint titer was detected again at the age of eight
years but no change in blocking or avidity index was observed.
In comparison to the Subject 1, the second child (Subject 2)
had considerably higher levels of GII.4-1999-specific cord
blood antibodies (endpoint titer 51,200) with BT90 100 and
avidity index 95%, which dropped by the age of six months
(Fig. 3 and Table 2). The primary NoV infection was acquired
between 1.5 and 2 years of age (Table 2), approximately a year
later than in the Subject 1 (Table 1). In addition, this infection
induced highly functional (BT90 100 and avidity index 99%)
GII.4-1999-specific antibodies. NoV RT-PCR and sequencing
of the stool samples detected NoV GII.2 genotype infection at
the age of 1 year and 9 months, prior to the first seroconver-
sion to NoV GII.4 VLPs at the age of two years (Table 2 and
Fig. 3). Correspondingly, an episode of AGE had been
recorded between the age of 17e24 months. Despite the high
levels of presumably protective antibodies at the age of two
years, another NoV infection already appeared during the next
year as indicated by the four-fold increase in BT90 at the age
of three. Judging by the seroconversion, the Subject 2 acquired
two additional NoV infections at the ages of five and eight
years (Table 2). Additionally, the Subject 2 had AGE symp-
toms at the age of 4.5 years, corresponding to seroconversion
at the age of 5 years.
Altogether, both subjects acquired at least three to four
NoV infections (Tables 1 and 2). The Subject 1 who had low
maternal antibody titer, lacking blocking activity and avidity,
acquired first infection already by the age of six months,
whereas the Subject 2, with a high titer and functionality of
maternal antibodies acquired first infection at least one year
Fig. 1. The integrity and morphology of NoV GII.4 VLPs as characterized by (A) western blot and (B) the electron micrograph examined by FEI Tecnai F12
electron microscope (Philips 487 Electron Optics, Holland). The protein weight marker is shown on the left lane and the purified NoV VLP on the right lane, using
a human convalescent serum against NoV GII.4 for detection.
Fig. 2. Norovirus GII.4-specific serum IgG responses during the first eight years of life in Subject 1. Serum specimens of the child were collected between March,
2000eMarch, 2008. Sera were analyzed at 1:100 dilution (OD 490 nm) and serially diluted to determine the endpoint titer (OD  0.1) for each sample.
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developed only at (Subject 2) or after (Subject 1) the two years
of age. Although the avidity remained high up to eight years
for both subjects, only the Subject 2 retained high level of
blocking antibodies. However, these GII.4-specific antibodies
did not protect the Subject 2 from a new infection prior to the
age of eight years with presumably NoV genotype highly
divergent to GII.4. Altogether, a positive correlation was
detected between BT90 and IgG endpoint titers (r ¼ 0.808,
P < 0.01) and avidity index (r ¼ 0.775, P < 0.01) of serum
antibodies in both subjects.
4. Discussion
In the present study we followed the development of NoV
GII.4-specific humoral immune responses in two children
from birth up to eight years of age. Seroconversion was
detected in at least three instances, suggesting a minimum of
three NoV GII infections in both children in eight years. NoV
GII.4 VLPs were chosen to measure antibody responses to GIINoVs as it is the most common genotype circulating for >20
years and causing sporadic acute gastroenteritis in children
worldwide [15,18,36]. Also, most infections in children during
the years 2000e2013 in Finland were caused by the GII.4
viruses [14,37].
In here, the routine stool specimens collected prior to two
years of age were used for determining possible NoV infec-
tion. For the Subject 1 NoV infections were not detected in the
stool samples collected at 4 and 5 months, although the
seroconversion happened at the six months of age. It is known
that NoV shedding can be highly variable, an average of 8e60
days [38] and therefore the infections may be readily missed if
the samples are not collected weekly. However, GII.2 NoV
infection of the Subject 2 was detected in a stool specimen
collected prior to blood sample taken at the age of 24 months,
when the first seroconversion was detected. The above result
shows that although a child may be infected with a diverse
NoV GII genotype it seroconverts to the GII.4 VLPs, as we
have previously shown [10,11]. NoV-specific cross-reactive
antibody epitopes are present in the N-terminal region of the
Table 1
NoV GII.4-1999 specific antibody responses in Subject 1. Shown are GII.4-
specific endpoint titers, GII.4-specific blocking titers (BT) 50 and 90 and
avidity indexes, (%).
Age
(months/years)
Presumed
infection
GII.4 endpoint
titer
Blocking
antibodies
Avidity
index (%)c
BT50
a BT90
b
0 m 3200 <50 <50 43
3 m 400 <50 <50 38
6 m x 3200d <50 <50 19
12 m 800 <50 <50 25
17 m 400 <50 <50 33
24 m 800 <50 <50 38
3 y x 6400d 200 100 95
4 y 1600 50 <50 67
5 y x 25,600d 100 <50 98
6 y 12,800 50 <50 75
7 y 6400 50 <50 82
8 y 12,800 <50 <50 69
a BT50, 50% blocking titer.
b BT90, 90% blocking titer.
c The avidity indexes >50% are shown in bold.
d >4-fold increase in antibody titer.
Fig. 3. Norovirus GII.4-specific serum IgG responses in Subject 2 from birth to eight years of age. Longitudinal serum samples were collected starting from cord
blood on April 9th, 2000. Serum specimens were analyzed at 1:100 dilution (OD 490 nm) and serially diluted to determine the endpoint titer (OD  0.1) for each
sample.
Table 2
NoV GII.4-1999 specific antibody responses in Subject 2. Shown are GII.4-
specific endpoint titers, GII.4-specific blocking titers 50 and 90 and avidity
indexes, (%).
Age
(months/years)
Presumed
infection
GII.4
endpoint titer
Blocking
antibodies
Avidity
index (%)c
BT50
a BT90
b
0 m 51,200 200 100 95
3 m 6400 <50 <50 91
6 m 1600 <50 <50 46
17 m 400 <50 <50 42
24 m x 102,400d 400 100 99
3 y x 204,800 800 400 99
4 y 51,200 200 100 96
5 y x 204,800d 1600 800 98
5.5 y 51,200 200 100 100
6 y 25,600 100 100 97
8 y x 102,400d 200 100 97
a BT50, 50% blocking titer.
b BT90, 90% blocking titer.
c The avidity indexes >50% are shown in bold.
d >4-fold increase in antibody titer.
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conversion using VLPs heterologous to the infecting genotype.
The titer, avidity and blocking ability of maternal anti-
bodies seemed to influence susceptibility of an infant to NoV
infection. The Subject 1 had a low level and low avidity of
maternally acquired antibodies and had the first NoV infection
early (<6 months of age), while the Subject 2 with high
maternal antibody level of high avidity was protected more
than 1.5 years. Interestingly, the Subject 2 was breastfed for
only three months in contrast to the Subject 1 who was
breastfed for 25 months indicating no protective role of
breastfeeding against NoV infection. Both children developed
high titer functional antibodies only at the age of two years or
later, probably because of the immaturity of the immune
system in an infant [22]. Avidity indexes of sequential serumsamples in the present study confirm the earlier findings that
the avidity is low in primary infections and increases over
time, possibly as a result of serial heterotypic infections [7,23].
Young children are able to generate homologous protective
blocking antibody titer (BT90 > 100) [10,19], which is asso-
ciated with greater protection from NoV infection and illness
[30], but are lacking heterologous blocking response and
therefore are prone to new infections by another NoV strain
[10]. We have recently reported that pre-existing blocking
antibody titers in acute sera were low in <2-year-old children
and only children above 12 months of age generated protective
cross-blocking antibodies following the infection, with the
endpoint titer >50,000 and BT90 > 100 [19]. In this study, at
the ages of four and six years of the Subject 2 the endpoint IgG
titer of 51,200 and BT90 100 did not protect from new NoV
268 V. Blazevic et al. / Microbes and Infection 18 (2016) 263e269infection (Table 2), confirming the previously determined
protective endpoint titer >50,000 and BT90 > 100 [10].
Early adult experimental infection studies have shown
that NoV immunity following infection lasts up to six
months [21] but less than two years [20]. More recent adult
NoV challenge studies showed duration of NoV blocking
antibodies up to six months [28]. Our results in naturally
infected children support these findings. We found
maximum duration of protection up to 3 years at older age,
which contradicts calculations by a mathematical model
that estimated four to eight years' duration of protective
immune response to NoV [40]. It is possible that some in-
fections with GI or non-GII.4 NoV were missed in this
study as only GII.4-1999 VLPs were used in the analyses,
but what we detected is the minimum number of infections.
We have earlier studied homologous and cross-reactive
antibody responses in GII.4-2010 New Orleans infected
children [10,19] and found that 100% of 6e18 month old
children seroconverted to GII.4-2010 NO and GII.4-2012
Sydney [19] and 67% to GII.4-1999, but only 17% to
more distant GII.12 NoV [10]. However, as the most com-
mon strains circulating in Finnish children at the time of the
sample collection in the present study were closely related
to GII.4-1999 (e.g. GII.4-US95/96, GII.4-2001, Farm-
ington-2002 and 2006) [14,41], these infections were likely
detected by the seroconversion to GII.4-1999 VLPs.
Previous studies in large cohorts [24,36] as well as our
own work [11] have suggested that a child may encounter
1e3 NoV infections within the first year of life. The results
in here confirm these findings and also show that at least
three infections are encountered by a child by the age of
five years. Vaccination of infants against NoV would
address the most common cause of hospitalizations due to
gastroenteritis in children in countries where universal
rotavirus vaccination is implemented [42]. Our results
suggest that vaccine should be delivered the earliest to the
one-year-old since before that age the immune system is
immature. Women of a childbearing age could be consid-
ered as a vaccine target population to protect young infants.
Even though this study is based on two subjects only, the
results in this study add to the understanding of immuno-
genicity and duration of protection in infants and young
children.
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